BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer. (February 2021)

• Record Type: Journal Article
• Authors: Ros, Javier; Baraibar, Iosune; Sardo, Emilia; Mulet, Nuria; Salvà, Francesc; Argilés, Guillem; Martini, Giulia; Ciardiello, Davide; Cuadra, José Luis; Tabernero, Josep; Élez, Elena
• Is Part Of: Therapeutic advances in medical oncology. Volume 13(2021)
• Publication Date: 2021-02
• Subjects: BEACON clinical trial -- binimetinib -- BRAF inhibitor -- BRAF V600E mutation -- colon cancer -- EGFR inhibitor -- encorafenib -- MEK inhibitor; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.994005
• DOI: 10.1177/1758835921992974
• Languages: English
• ISSNs: 1758-8340

Abstract

Introduction: BRAF driver mutations are found in up to 15% of patients with colorectal cancer (CRC) and lead to constitutive activation of BRAF kinase and sustained RAS/RAF/MEK/ERK pathway signaling. BRAF mutations define a sub-population characterized by a poor prognosis and dismal median survival. Following successful outcomes with BRAF inhibition in BRAF mutant metastatic melanoma, this approach was evaluated in metastatic colorectal cancer (mCRC). The development and combination of targeted therapies against multiple signaling pathways has proved particularly successful, with improved survival and response rates. Areas covered: This review addresses the development of therapeutic strategies with inhibitors targeting MAPK/ERK and EGFR signaling in BRAF V600E mutated mCRC, focusing on encorafenib, binimetinib and cetuximab. A pharmacological and clinical review of these drugs and the therapeutic approaches behind their optimization are presented. Expert opinion: Exploiting knowledge of the mechanisms of resistance to BRAF inhibitors has been crucial to developing effective therapeutic strategies in BRAF-V600E mutant mCRC. The BEACON trial is a successful example of this approach, using encorafenib and cetuximab with or without binimetinib in patients with previously treated BRAF V600E mutant mCRC, showing an impressive improvement in clinical outcomes and tolerable toxicity compared with chemotherapy, establishing a new standard of care in this setting.